SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Pts With Recurrent Platinum-Resistant Ovarian Cancer"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Pts With Recurrent Platinum-Resistant Ovarian Cancer"

By Insights from 2024 SGO Annual Meeting FEATURING Nicoletta Colombo

0 views

March 26, 2024

Comments 0

The Importance of HRD Testing in Advanced Ovarian Cancer

Feat. M. Markman

Best Practices for the management of ocular adverse events associate…

Feat. K. Lamoreau

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton

27:04

Fengting Yan

Cancer Screening Molecular Tools

09:06

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

Feat. R. Salani

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

14:45

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

Feat. M. Raza Mirza

11:15

Total Health

2024 Updates in Ovarian Cancer

Feat. T. Tillmanns

06:07

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza

04:43

Treatment Approach for Advanced Ovarian Cancer

The Role Of Folate Receptor Alpha In Ovarian Cancer

Feat. D. M. O'Malley

06:47

UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang

15:45

Michael Birrer

Defining Platinum Resistance in Ovarian Cancer

13:15

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced En…

Feat. A. Karam

06:50

Fengting Yan

Year in Review: Ovarian Cancer

27:14

David Tan

Management of Recurrent Ovarian Clear Cell Carcinoma

15:14

Brian Slomovitz

Update in Vulvar and Vaginal Cancer

25:10

Yale School of Medicine

Ovarian Cancer Prevention and Early Detection - Ovarian Cancer Does …

Feat. M. Minkin, E. Ratner

06:23

Total Health

Recent Highlights in Ovarian Cancer

Feat. B. Slomovitz

17:20

UCLA Health

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

Feat. G. Konecny

18:16

Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "Antibody-Drug Conjugates in Ovarian Cancer…

Feat. J. Kurtz

01:41

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Unveiling the Unique Identity of Clear-Cel…

Feat. F. Blanc-Durand

14:40

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "BrUOG 354 Trial Final Results - Nivo vs. …

Feat. D. Dizon

Login

Login

Join VuMedi

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Pts With Recurrent Platinum-Resistant Ovarian Cancer"

Recommended